Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Valsartan/Amlodipine 160/5 mg or 160/10 mg Versus Valsartan 160 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Valsartan 160 mg Monotherapy

NCT00170963 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00170963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00170963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Valsartan/Amlodipine 160/5 mg or 160/10 mg Versus Valsartan 160 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Valsartan 160 mg Monotherapy
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2004
Completion date
June 30, 2005
Enrollment
1,018 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension